Promoting Equitable Access and Community Adoption of HER2-Targeted Therapies

This segment focuses on strategies to ensure equitable access to novel HER2-targeted therapies and the dissemination of knowledge to community clinicians. Dr. Gradishar highlights that equitable access extends beyond prescribing the drug: it requires addressing financial toxicity, logistical barriers, and reliable biomarker testing. Many patients face high out-of-pocket costs or insurance hurdles, making clinician awareness of coverage options, patient assistance programs, and co-pay support essential. Equitable access also depends on the availability of subspecialists to manage therapy-related toxicities. For example, timely access to pulmonologists, ophthalmologists, or imaging services can determine whether patients safely receive advanced therapies. When local expertise is limited, clinicians can establish networks with tertiary centers or academic colleagues to support patient care.

Biomarker testing is another critical component. Accurate HER2 testing ensures that patients receive therapies appropriate to their HER2 status, particularly as emerging treatments target HER2-low and ultra-low subtypes. Additionally, the logistical burden of frequent infusions can limit access, especially for patients in rural or remote areas. Innovations such as subcutaneous formulations are anticipated to reduce travel demands and improve accessibility.

The panel also emphasized the importance of knowledge dissemination for community adoption. Interactive learning formats, such as case discussions and digital “snackable” content, are more effective than traditional lectures. Pharmaceutical companies and virtual focus groups can provide additional resources for both clinicians and patients. By combining proactive education, financial and logistical support, and robust professional networks, clinicians can help expand access to HER2-targeted therapies across diverse practice settings, ultimately improving patient outcomes.

The discussion concludes with reflections on the rapidly evolving HER2 field, the critical role of patient input, and the ongoing excitement about translating emerging data into practical, patient-centered care.